MANY AMERICANS STRUGGLE TO PAY FOR OUR MEDICINES AND WE ARE FOCUSED
ON WORKING COLLABORATIVELY TOWARD SUSTAINABLE SOLUTIONS
We recognize that people with diabetes are finding it harder to pay
for their healthcare, including the medicines we make. As a company
focused on improving the lives of people with diabetes, this is not acceptable.
Ensuring access and affordability is a responsibility we share with
all involved in healthcare and we are going to do our part. We believe
the challenges that patients face are due to a complex healthcare
system that continues to evolve. The best approach to viable solutions
is through collaboration among pharmaceutical companies, payers,
pharmacy benefit managers (PBMs), insurance companies, employers,
patient organizations and policy makers.
We welcome and will actively seek collaborations leading to
sustainable solutions based on the following three tenets, which we
believe are key to making a positive impact on affordability for patients.
Transforming the complex pricing system: When it comes to
drug pricing, the system can be improved. The system we currently
have is very complicated – rebates, discounts, administrative fees,
co-pays and deductibles all play a role in what our customers, and
people with diabetes, pay. We need to work with all involved to
simplify and transform the system.
Creating more pricing predictability: We recognize that
customers like PBMs and payers have to effectively manage their
healthcare budgets, including anticipating and planning for price
increases. We want to be supportive of those efforts. One action we
are taking today in support of that is to limit any potential future
list price increases to no more than single-digit percentages
Reducing the burden of out of pocket costs: It’s well
documented that a growing number of people with high-deductible
health plans – health coverage with lower premiums – face higher
costs at the pharmacy counter. While high-deductible health plans
were designed to lower costs overall, the reality is that people
with diabetes are forced to pay more out-of-pocket. We’re committed
to several approaches:
Continuing our investments in co-pay assistance programs.
Our programs will help reduce the out-of-pocket burden for
patients, and we will continue our efforts to minimize the
effect list prices might have on patients in high deductible
Maintaining a patient assistance program. To learn more
about our patient assistance programs and how to apply, click here or call 866-310-7549.
Ensuring that there is always a lower-priced treatment option
available in the form of human insulin.
Engaging in policy discussions to make sure people living
with diabetes have the best coverage possible.
Novo Nordisk's global position on pricing